Acadia listing price is US$575,000 to US$595,000. Will Royalties be calculated on US$575,000 or US$375,000?
I suspect the royalties will be calculated on the sale price less some selling cost as “net sales” which should be higher than net realised cost of US$375,000, imo.
Acadia's rare-disease drug to cost $575,000 to $595,000
Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-117
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.92 |
Change
0.610(4.58%) |
Mkt cap ! $1.668B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $13.99 | $12.96 | $3.629M | 267.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 263 | $13.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.92 | 30 | 2 |
View Market Depth
| Last trade - 11.44am 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |